In solid tumors, MSI2 has been shown to promote non-small cell lung cancer (NSCLC) metastasis via TGF-β signaling [14], and promote pancreatic cancer development and drug resistance [15, 16]. Here, TGFB1 is linked to non-small cell lung carcinoma.